Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

BACKGROUND: Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP). METHODS: Ipilimumab was available upon physician request for patients aged 16 or over with pretreated sta...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ascierto, Paolo A, Simeone, Ester, Sileni, Vanna Chiarion, Pigozzo, Jacopo, Maio, Michele, Altomonte, Maresa, Del Vecchio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, Ridolfi, Ruggero, Cognetti, Francesco, Testori, Alessandro, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Mandalà, Mario, Cimminiello, Carolina, Rinaldi, Gaetana, Aglietta, Massimo, Queirolo, Paola
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2014
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4030525/
https://ncbi.nlm.nih.gov/pubmed/24885479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-116
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы